COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone81Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/498b805accd94d8884073e3f5a8b38df |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:498b805accd94d8884073e3f5a8b38df |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:498b805accd94d8884073e3f5a8b38df2021-12-02T02:12:27ZCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features1176-63281178-2021https://doaj.org/article/498b805accd94d8884073e3f5a8b38df2008-03-01T00:00:00Zhttp://www.dovepress.com/comt-inhibition-with-tolcapone-in-the-treatment-algorithm-of-patients--a990https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone81Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di Scienze Neurologiche, Università di Napoli Federico II, Naples, Italy; 4University of Pisa, Department of Neuroscience, Pisa, Italy; 5Department of Neuroscience, University of Turin, Turin, Italy; 6Department of Oncology and Neuroscience, University G D’Annunzio, G D’Annunzio Foundation CESI, Chieti-Pescara, Italy; 7Department of Neurosciences, University of Catania; 8Institute of Neurology, University “Magna Græcia,” Catanzaro, ItalyAbstract: Levodopa is the most effective treatment in Parkinson’s disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce “off” time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.Keywords: Parkinson’s disease, levodopa, motor fluctuations, COMT inhibitors, tolcapone Angelo AntoniniGiovanni AbbruzzesePaolo BaroneUbaldo BonuccelliLeonardo Lopianoet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 1, Pp 1-9 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Angelo Antonini Giovanni Abbruzzese Paolo Barone Ubaldo Bonuccelli Leonardo Lopiano et al COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| description |
Angelo Antonini1, Giovanni Abbruzzese2, Paolo Barone3, Ubaldo Bonuccelli4, Leonardo Lopiano5, Marco Onofrj6, Mario Zappia7, Aldo Quattrone81Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy; 2Movement Disorder Unit, Neurology, University of Genoa, Genoa, Italy; 3Dipartimento di Scienze Neurologiche, Università di Napoli Federico II, Naples, Italy; 4University of Pisa, Department of Neuroscience, Pisa, Italy; 5Department of Neuroscience, University of Turin, Turin, Italy; 6Department of Oncology and Neuroscience, University G D’Annunzio, G D’Annunzio Foundation CESI, Chieti-Pescara, Italy; 7Department of Neurosciences, University of Catania; 8Institute of Neurology, University “Magna Græcia,” Catanzaro, ItalyAbstract: Levodopa is the most effective treatment in Parkinson’s disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce “off” time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.Keywords: Parkinson’s disease, levodopa, motor fluctuations, COMT inhibitors, tolcapone |
| format |
article |
| author |
Angelo Antonini Giovanni Abbruzzese Paolo Barone Ubaldo Bonuccelli Leonardo Lopiano et al |
| author_facet |
Angelo Antonini Giovanni Abbruzzese Paolo Barone Ubaldo Bonuccelli Leonardo Lopiano et al |
| author_sort |
Angelo Antonini |
| title |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| title_short |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| title_full |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| title_fullStr |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| title_full_unstemmed |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features |
| title_sort |
comt inhibition with tolcapone in the treatment algorithm of patients with parkinson’s disease (pd): relevance for motor and non-motor features |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/498b805accd94d8884073e3f5a8b38df |
| work_keys_str_mv |
AT angeloantonini comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures AT giovanniabbruzzese comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures AT paolobarone comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures AT ubaldobonuccelli comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures AT leonardolopiano comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures AT etal comtinhibitionwithtolcaponeinthetreatmentalgorithmofpatientswithparkinsonamprsquosdiseasepdrelevanceformotorandnonmotorfeatures |
| _version_ |
1718402591051743232 |